Gilead Acquires Sprint Bioscience's TREX1 Cancer Program in $414 Million Deal
核心洞察
Gilead Sciences acquired Sprint Bioscience (搜索)'s preclinical TREX1 (搜索) cancer program for $14 million upfront plus up to $400 million in milestone payments.
TREX1 (搜索) is a first-in-class immuno-oncology target that helps tumors evade immune detection by degrading cytosolic DNA that would normally trigger immune responses.
Preclinical data showed TREX1 (搜索) inhibition activates interferon pathways, slows tumor growth, and increases immune cell infiltration, potentially enhancing responses to multiple cancer therapies.
Gilead Sciences has acquired Sprint Bioscience (搜索)'s preclinical TREX1 (搜索) cancer program in a deal worth $14 million upfront and up to $400 million in potential milestone payments, marking another strategic move by the pharmaceutical giant to bolster its oncology pipeline following recent setbacks.
The acquisition announced Monday centers on TREX1 (搜索) (Three-prime repair exonuclease 1), a first-in-class immuno-oncology target that represents a novel approach to cancer treatment. Research indicates that while a healthy TREX1 gene helps prevent overactivation of the immune system that leads to conditions such as lupus, it may also enable cancer cells to hide from the body's natural immune defenses.
Novel Mechanism of Action
TREX1 (搜索) helps tumors evade immune detection by degrading cytosolic DNA that would normally trigger an immune response. Sprint Bioscience (搜索)'s inhibitors work by blocking TREX1, forcing tumors to expose themselves to immune surveillance. "TREX1 has demonstrated significant potential in the preclinical phase," said Sprint Bioscience CEO Johan Emilsson.
Preclinical data presented at AACR IO 2025 demonstrated that TREX1 (搜索) inhibition activates interferon pathways, slows tumor growth, and increases immune cell infiltration. These findings suggest the target could enhance responses to immunotherapies, chemotherapy, and radiotherapy across multiple tumor types.
Strategic Context for Gilead
The acquisition comes as Gilead faces challenges in its oncology division. The company's $21 billion acquisition of Immunomedics five years ago brought the cancer drug Trodelvy, which has failed to meet initial expectations while encountering research setbacks. In 2024, Gilead announced it would no longer sell Trodelvy for bladder cancer after a study failed to confirm the medicine's clinical benefits.
Gilead is also confronting increased competition in its cell therapy business and regulatory uncertainty in its HIV franchise under the Trump administration's targeting of HIV programs. The company has been actively seeking external opportunities, including a $350 million deal in August to acquire Interius BioTherapeutics (搜索) and its technology for genetically modifying immune cells inside the body.
Sprint Bioscience's Strategic Approach
For Sprint Bioscience (搜索), the deal represents a strategic milestone that provides non-dilutive funding while validating the company's discovery platform. The Swedish biotech, founded in 2009, focuses on early-stage drug discovery using a fragment- and structure-based platform to design highly selective small-molecule inhibitors.
The company's business model involves developing preclinical assets to the point of biological validation before monetizing them through sales or licensing to larger pharmaceutical companies. This approach allows Sprint to de-risk projects while reinvesting in new oncology programs. CEO Emilsson noted the move reflects a strategic shift toward flexible, value-driven exits.
Clinical Implications
For Gilead, TREX1 (搜索) complements existing immuno-oncology therapies by activating innate immune pathways, potentially improving outcomes across multiple tumor types. The target's ability to enhance responses to various cancer treatments positions it as a potentially valuable addition to combination therapy regimens.
The deal structure minimizes risk for Gilead, as the vast majority of the proposed payouts are contingent on the program's success in meeting clinical, regulatory, and commercial milestones. This acquisition strengthens Gilead's position in the emerging field of innate immune reactivation while providing Sprint Bioscience (搜索) with the resources to advance other preclinical projects.